{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:03:44Z","timestamp":1783569824375,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clml.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:47:50Z","timestamp":1660560470000},"page":"912-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-4027","authenticated-orcid":false,"given":"Tahani","family":"Atieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-3707","authenticated-orcid":false,"given":"Justin","family":"Riffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.08.003_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.08.003_bib0002","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.003_bib0003","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.003_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.08.003_bib0005","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.08.003_bib0006","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.08.003_bib0007","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"10.1016\/j.clml.2022.08.003_bib0008","unstructured":"Kanapuru B, editor BLA 761158: Belantamab mafodotin2020."},{"key":"10.1016\/j.clml.2022.08.003_bib0009","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clml.2022.08.003_bib0010","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau TMaG","year":"2000"},{"key":"10.1016\/j.clml.2022.08.003_bib0011","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2021-146047","article-title":"SEA-BCMA, an investigational nonfucosylated monoclonal antibody: ongoing results of a phase 1 study in patients with relapsed\/refractory multiple myeloma (SGNBCMA-001)","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.003_bib0012","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.003_bib0013","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.08.003_bib0014","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.003_bib0015","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/bjh.17302","article-title":"Melflufen plus dexamethasone in relapsed\/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1","volume":"193","author":"Bringhen","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.08.003_bib0017","unstructured":"Oncopeptides withdraws Pepaxto\u00ae in US, scale down organization and focus on R&D [press release]. October 22, 2021 2021."},{"key":"10.1016\/j.clml.2022.08.003_bib0018","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.08.003_bib0019","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2022.08.003_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2021.07.036","article-title":"Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis","volume":"156","author":"Mohyuddin","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.08.003_bib0021","doi-asserted-by":"crossref","unstructured":"Shragai T, Gatt, M., Jarchowsky, O., et\u00a0al, editor Real-World Outcomes of Belantamab Mafodotin Treatment for Patients with Relapsed\/Refractory Myeloma via GSK Expanded Access Program. European Hematology Association; 2020 11\/19\/2020; Virtual","DOI":"10.1177\/2040620720979813"},{"key":"10.1016\/j.clml.2022.08.003_bib0022","volume":"2021","author":"Trudel","year":"2021"},{"key":"10.1016\/j.clml.2022.08.003_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"Real-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma\u2014the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:26Z","timestamp":1761871226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2152265022002555"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}